Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
Butler et al., The Lancet, doi:10.1016/S0140-6736(21)00461-X
https://c19early.org/butler4.html